- Home
- KALA vs IMA Comparison
KALA vs IMA Comparison
Compare KALA & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KALA | IMA |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.8M | 66.3M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | KALA | IMA |
|---|---|---|
| Price | $1.69 | $5.90 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $31.50 | $16.00 |
| AVG Volume (30 Days) | ★ 142.2K | 13.1K |
| Earning Date | 04-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 67.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $3.94 |
| 52 Week High | $20.58 | $17.50 |
Technical Indicators
Market Signals| Indicator | KALA | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 38.94 | 58.17 |
| Support Level | $0.32 | $5.29 |
| Resistance Level | $1.81 | $6.06 |
| Average True Range (ATR) | 0.45 | 0.30 |
| MACD | -0.17 | 0.04 |
| Stochastic Oscillator | 3.85 | 82.19 |
Price Performance
Historical ComparisonAbout KALA KALA BIO Inc.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.